Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Properties of CD34 + CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate

Xiaoyan Jiang, Donna Forrest, Franck Nicolini, Ali Turhan, Joelle Guilhot, Calvin Yip, Tessa Holyoake, Heather Jorgensen, Karen Lambie, Kyi Min Saw, Emily Pang, Ranko Vukovic, Paeta Lehn, Ashley Ringrose, Miao Yu, Ryan R. Brinkman, Clay Smith, Allen Eaves, Connie Eaves

Blood (2010) 116 (12): 2112–2121.

https://doi.org/10.1182/blood-2009-05-222471

Published: 2010

Includes: Supplemental data

Journal Articles

Properties of CD34 + CML Cells That Predict Clinical Response to Tyrosine Kinase Inhibitors.

Xiaoyan Jiang, MD, PhD, Donna Forrest, MD, Franck Nicolini, MD, PhD, Karen Lambie, Kyi Min Saw, Emily Pang, Ranko Vukovic, Clayton Smith, MD, Allen Eaves, MD, PhD, Connie Eaves, PhD

Blood (2007) 110 (11): 324.

https://doi.org/10.1182/blood.V110.11.324.324

Published: 2007

Journal Articles

Stable Suppression of a Novel Oncogene, AHI-1, in Human Cutaneous T-Cell Leukemia Cells Normalizes Its Transforming Activity In Vitro and In Vivo and Aberrant Expression of AHI-1 Is Also Present in Leukemic Sezary Cells from Patients with Sezary Syndrome.

Ashley Ringrose, Youwen Zhou, MD, Emily Pang, Ann E.-J. Lin, Xiao-Jiang Li, PhD, Irene Li, Andrew Weng, MD, PhD, Xiaoyan Jiang, MD, PhD

Blood (2005) 106 (11): 2605.

https://doi.org/10.1182/blood.V106.11.2605.2605

Published: 2005

Journal Articles

Transplantation of Immunodeficient Mice with Chronic Myeloid Leukemia (CML) Cells from Chronic Phase Patients Reveals a Hierarchy of CD34 + Aldehyde Dehydrogenase-Positive Cells with Short- and Long-Term Repopulating Activity and Transient Responsiveness to Imatinib Mesylate in Vivo.

Oliver Christ, MD, Wolfgang Eisterer, MD, Xiaoyan Jiang, MD, PhD, Emily Pang, Karen Leung, Clayton Smith, MD, Allen C. Eaves, MD, PhD, Connie J. Eaves, PhD

Blood (2004) 104 (11): 2960.

https://doi.org/10.1182/blood.V104.11.2960.2960

Published: 2004

Journal Articles

Leukemic Stem Cells of Chronic Phase CML Patients Consistently Display Very High BCR-ABL Transcript Levels and Reduced Responsiveness to Imatinib Mesylate in Addition to Generating a Rare Subset That Produce Imatinib Mesylate-Resistant Differentiated Progeny.

Xiaoyan Jiang, MD, PhD, Yun Zhao, PhD, Wing Yiu Chan, Emily Pang, Allen Eaves, MD, PhD, Connie Eaves, PhD.

Blood (2004) 104 (11): 711.

https://doi.org/10.1182/blood.V104.11.711.711

Published: 2004

Journal Articles

Deregulated expression in Ph + human leukemias of AHI-1 , a gene activated by insertional mutagenesis in mouse models of leukemia

Xiaoyan Jiang, Yun Zhao, Wing-Yiu Chan, Suzanne Vercauteren, Emily Pang, Sean Kennedy, Frank Nicolini, Allen Eaves, Connie Eaves

Blood (2004) 103 (10): 3897–3904.

https://doi.org/10.1182/blood-2003-11-4026

Published: 2004

NARROW

Properties of CD34 + CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate

Properties of CD34 + CML Cells That Predict Clinical Response to Tyrosine Kinase Inhibitors.

Stable Suppression of a Novel Oncogene, AHI-1, in Human Cutaneous T-Cell Leukemia Cells Normalizes Its Transforming Activity In Vitro and In Vivo and Aberrant Expression of AHI-1 Is Also Present in Leukemic Sezary Cells from Patients with Sezary Syndrome.

Transplantation of Immunodeficient Mice with Chronic Myeloid Leukemia (CML) Cells from Chronic Phase Patients Reveals a Hierarchy of CD34 + Aldehyde Dehydrogenase-Positive Cells with Short- and Long-Term Repopulating Activity and Transient Responsiveness to Imatinib Mesylate in Vivo.

Leukemic Stem Cells of Chronic Phase CML Patients Consistently Display Very High BCR-ABL Transcript Levels and Reduced Responsiveness to Imatinib Mesylate in Addition to Generating a Rare Subset That Produce Imatinib Mesylate-Resistant Differentiated Progeny.

Deregulated expression in Ph + human leukemias of AHI-1 , a gene activated by insertional mutagenesis in mouse models of leukemia

Email alerts

ASH Publications

American Society of Hematology

Properties of CD34 + CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate

Properties of CD34 + CML Cells That Predict Clinical Response to Tyrosine Kinase Inhibitors.

Stable Suppression of a Novel Oncogene, AHI-1, in Human Cutaneous T-Cell Leukemia Cells Normalizes Its Transforming Activity In Vitro and In Vivo and Aberrant Expression of AHI-1 Is Also Present in Leukemic Sezary Cells from Patients with Sezary Syndrome.

Transplantation of Immunodeficient Mice with Chronic Myeloid Leukemia (CML) Cells from Chronic Phase Patients Reveals a Hierarchy of CD34 + Aldehyde Dehydrogenase-Positive Cells with Short- and Long-Term Repopulating Activity and Transient Responsiveness to Imatinib Mesylate in Vivo.

Leukemic Stem Cells of Chronic Phase CML Patients Consistently Display Very High BCR-ABL Transcript Levels and Reduced Responsiveness to Imatinib Mesylate in Addition to Generating a Rare Subset That Produce Imatinib Mesylate-Resistant Differentiated Progeny.

Deregulated expression in Ph + human leukemias of AHI-1 , a gene activated by insertional mutagenesis in mouse models of leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only